AHRQ Examines Impact of Payment Policies on Clinical Trials
AHRQ Examines Impact of Payment Policies on Clinical Trials
The Agency for Healthcare Research and Quality (AHRQ) has released a draft paper examining the impact of changes in payment policies on clinical trials. The report discusses the relationship between third-party payments and the recruitment and retention of participants in clinical trials. Among the conclusions of the report: payment policies do affect evidence development in that their impact on clinical trial enrollment results in slower accrual, longer time to complete studies, and the occasional early termination of a study due to a lack of participation. Further, the reports suggest that better coordination among government agencies and between government, third-party payors, sponsors, and trial sites is necessary. Comments on the report are due Jan. 23.
Information: Go to http://www.ahrq.gov/clinic/ta/paypolicy/paypolicy.pdf
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
